Guselkumab as a Possible New Treatment for Psoriasis

Abstract

Introduction: In Mexico it affects approximately 2 million people, with a significant impact on quality of life and difficult to manage. Theoretical framework:The lesion it causes is round, salmon-pink papules and plaques, located on knees, elbows and scalp. The diagnosis is mainly clinical and the treatment will depend on the affected body surface and the location. The drugs considered first line are topical and second line drugs are used systemically, which in many occasions have adverse effects that make attachment difficult. Guselkumab, a drug approved in 2017, is an IgG1 that blocks the p19 subunit of IL-23.Discussion: Guselkumab, which is a monoclonal antibody, provides better patient outcomes compared to the drugs used in current therapeutics. There is little information currently available on Guselkumab since it has only recently been approved, butin all studies it has shown to be superior to other monoclonal antibodies, the main disadvantage being that it is not currently available in Mexico and the long administration time.Conclusion: Researching new drugs helps us to provide the patient with atreatment with the least amount of adverse effects, achieving greater adherence and better control of the disease.

Authors and Affiliations

Ingrid Pamela Rodríguez Minguela ,María Fernanda Gámez Acosta ,Zuleyka Roxana Martínez Martínez , Edit Cano Muñoz , Alfredo López Gómez ,Nallely Olivera Ruiz , Monserrat Espinosa Ramos

Keywords

Related Articles

True Knot of the Umbilical Cord and its Implications in the Fetal Well-Being

The true knot of the umbilical cord is a pathology with a relatively low incidence. However, it is associated with the risk of loss of fetal well-beingand in severe cases with perinatal death.There are b...

An Overview of Hypertensive States During Pregnancy for Primary Care Physicians

With the aim of informing the first contact physician about the hypertensive states of pregnancy, we carried out this bibliographic review. Sources in English and Spanish were consulted for the writing of this article....

Case Series of Mucormycosis in Post COVID 19 Patients with Hematological Malignancies in Ongoing Pandemic

Rhinocerebral mucormycosis is a lethal infection caused by saprophytic fungi in immunocompromised patients. Haematological malignancy patients with superseeded COVID 19 infection are more predisposed to mucormycosis with...

The Efficacy of Zinc Supplementation for Accelerate Bone Healing and Reduce Edema, Trismus and Pain as Post-Operative Sequelae in Maxillofacial Surgery: A Literature Review

Maxillofacial surgeryinvolves an operation to correct a disease, injury or defect of face, jaw or mouth. Recently some strategies have been developed for minimizing postoperative discomfort after maxillofacial...

Delirium Management in the Critic Geriatric Patient: An Updated Approach

Delirium or acute confusional syndrome is a common problem in geriatric patients, although itsdiagnosis is often overlooked, especially in its hypoactive form. Risk factors for delirium are previous cognitiv...

Download PDF file
  • EP ID EP740091
  • DOI 10.47191/ijmscrs/v3-i5-04
  • Views 52
  • Downloads 0

How To Cite

Ingrid Pamela Rodríguez Minguela, María Fernanda Gámez Acosta, Zuleyka Roxana Martínez Martínez, Edit Cano Muñoz, Alfredo López Gómez, Nallely Olivera Ruiz, Monserrat Espinosa Ramos (2023). Guselkumab as a Possible New Treatment for Psoriasis. International Journal Of Medical Science And Clinical Research Studies, 3(5), -. https://www.europub.co.uk/articles/-A-740091